These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Two heterogeneously vancomycin-intermediate clinical isolates of methicillin-sensitive and methicillin-resistant Staphylococcus aureus in a Turkish university hospital: brief report of a surveillance study. Torun MM, Bahar H, Demirci M, Altaş K, Bağdatli Y, Kocazeybek B, Kapi M, Hiramatsu K. Int J Antimicrob Agents; 2005 Dec; 26(6):508-10. PubMed ID: 16256313 [No Abstract] [Full Text] [Related]
44. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA. J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520 [Abstract] [Full Text] [Related]
50. Design and synthesis of benzenesulfonanilides active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Namba K, Zheng X, Motoshima K, Kobayashi H, Tai A, Takahashi E, Sasaki K, Okamoto K, Kakuta H. Bioorg Med Chem; 2008 Jun 01; 16(11):6131-44. PubMed ID: 18468909 [Abstract] [Full Text] [Related]
52. The emergence of mupirocin resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Trinidad: a first report. Orrett FA. Jpn J Infect Dis; 2008 Mar 01; 61(2):107-10. PubMed ID: 18362397 [Abstract] [Full Text] [Related]
58. Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014). Mendes RE, Sader HS, Smart JI, Castanheira M, Flamm RK. Eur J Clin Microbiol Infect Dis; 2017 Jun 01; 36(6):1013-1017. PubMed ID: 28111724 [Abstract] [Full Text] [Related]